Clinical Trial Update: Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II trial evaluating lenalidomide with subcutaneous bortezomib and dexamethasone for newly diagnosed multiple myeloma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-04